Strumento inattivo

Azioni Durata Therapeutics Inc

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

Durata Therapeutics : Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults	01/06/15
Durata Therapeutics : Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections	27/05/15
Durata Therapeutics : Actavis Confirms Generic Letairis® Patent Challenge	08/04/15
Durata Therapeutics : Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors	03/04/15
Durata Therapeutics : Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan	12/03/15

Settore

	Variaz. 1 gen.	Capi.
MODERNA, INC.	+25,69%	47,86 Mrd
LONZA GROUP AG	+46,90%	41,42 Mrd
IQVIA HOLDINGS INC.	-3,46%	40,66 Mrd
CELLTRION, INC.	-6,20%	28,92 Mrd
ICON PUBLIC LIMITED COMPANY	+9,17%	25,55 Mrd
ALNYLAM PHARMACEUTICALS, INC.	-20,42%	19,27 Mrd
MEDPACE HOLDINGS, INC.	+28,07%	12,14 Mrd
BIO-TECHNE CORPORATION	+0,17%	12,15 Mrd
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1,24%	11,99 Mrd